A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Trial summary:
The TORPEdO trial compares toxicity outcomes at 12 months for patients with oropharyngeal cancer, randomised to either photons (IMRT) or protons (IMPT). Randomisation has a 2:1 weighting in favour of proton treatment. A total of 183 patients will be recruited.
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | | ||
| Planning Benchmark Case | | ||
| Dummy Run | |||
| During Accrual | Individual Case Review | | Prospective: Outlining for all patients, planning for first case. Retrospective: all patients |
| Data collection | | All plans, replans and CBCT data | |
| Dosimetry | | ||
| QA Streamlining | | CompARE, NIMRAD, DARS and PATHOS |
RTTQA contact: torpedoqa.enh-tr@nhs.net
Chief investigator: Dr David Thomson (The Christie NHS Foundation Trust)
Sponsor: The Institute of Cancer Research (TORPEdO-icrctsu@icr.ac.uk)
Funder: Cancer Research UK